-
- Tomita Taisuke
- Department of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo
Bibliographic Information
- Other Title
-
- 認知症への先制医療:アミロイド蓄積をいつ,どのように防ぐか
- ニンチショウ エ ノ センセイ イリョウ : アミロイド チクセキ オ イツ,ドノ ヨウ ニ フセグ カ
Search this article
Description
Amyloid-βpeptide (Aβ) is the major component of senile plaques deposited in the brains of patients with Alzheimer disease (AD). Several lines of evidence suggest that the accumulation of A βis linked to the pathogenesis of AD. A βis derived from amyloid-βprecursor protein (APP) that is sequentially cleaved by two aspartate proteases, β- and γ- secretases. Advances in basic research and observational study implicate that that drugs that inhibit or modulate the proteolytic activity of these secretases could provide a disease- modifying therapy against AD as pre- emptive medicine. In addition, evolutional genome sequencing technologies reveal several genetic risk factors, which may impact on the onset of AD. In this review, I will discuss about recent status regarding the development of therapeutics for AD.
Journal
-
- Japanese Journal of Biological Psychiatry
-
Japanese Journal of Biological Psychiatry 24 (4), 179-184, 2013
Japanese Society of Biological Psychiatry
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282680389206528
-
- NII Article ID
- 130005395515
-
- NII Book ID
- AA12468060
-
- ISSN
- 21866465
- 21866619
-
- NDL BIB ID
- 025132187
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL
- CiNii Articles
-
- Abstract License Flag
- Disallowed